Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

The market is a sea of red on Thursday but that isn't stopping the Mesoblast Ltd (ASX: MSB) share price from rocketing.

In morning trade, the allogeneic cellular medicines developer's shares are up 30% to a 52-week high of $2.57.

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition

Image source: Getty Images

Why is the Mesoblast share price shooting higher?

Investors have been hitting the buy button this morning after the company made arguably the most important announcement in its history.

According to the release, the US Food and Drug Administration (FDA) has approved its Ryoncil (remestemcel-L) product as the first mesenchymal stromal cell (MSC) therapy in the United States.

Ryoncil is the only MSC therapy approved in the U.S. for any indication, and the only approved therapy for steroid-refractory acute graft versus host disease (SR-aGvHD) in children 2 months and older, including adolescents and teenagers. It is a life-threatening condition with high mortality rates.

The company highlights that annually in the United States approximately 10,000 patients undergo an allogeneic bone marrow transplant, 1,500 of whom are children.

Approximately 50% develop aGvHD and almost half of those do not respond to steroids, which is the recognised first-line treatment.

There is now hope for people that develop aGvHD. Mesoblast notes that in a single-arm multicenter phase 3 trial of children with SR-aGvHD, 89% of whom had high severity Grade C or Grade D disease, 70% achieved an overall response by day 28 of treatment with Ryoncil. This is a measure that predicts survival in aGVHD.

Ryoncil treatment was not discontinued or interrupted in any patient for any laboratory abnormality, and the full course was completed without interruption in more than 85% of patients.

Management commentary

Commenting on the US FDA's approval of Ryoncil, Mesoblast's chief executive, Dr. Silviu Itescu, said:

We are very pleased that the FDA has granted approval of RYONCIL and are proud of the company's commitment to the GVHD community in bringing this important new treatment to children and families with no other acceptable options.

Dr Itescu appears optimistic that this could be the first of further approvals of products in its portfolio. He adds:

With RYONCIL approval by FDA, Mesoblast has demonstrated the ability to bring the first MSC product to market. We will continue to work closely with FDA to obtain approval of our other late-stage products, including REVASCOR for cardiovascular diseases and rexlemestrocel-L for inflammatory pain indications, as well as expanding the indications for RYONCIL in both children and adults with inflammatory conditions.

The Mesoblast share price is now up approximately 750% since this time last year.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor with stethoscope typing on her computer.
Healthcare Shares

$128 million contract win: Are Pro Medicus shares a strong buy?

I remain a fan of this healthcare technology company, and today's announcement gives me another reason to be optimistic.

Read more »

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »